Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05851079
Other study ID # IRB-20210333-R
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 10, 2021
Est. completion date November 30, 2024

Study information

Verified date May 2023
Source Women's Hospital School Of Medicine Zhejiang University
Contact Hui Wang, PhD
Phone 0571-89998857
Email wang71hui@zju.deu.cn
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The goal of this observational study is to compare the accuracy and sensitivity of High-throughput human papilloma virus(HPV) typing and integrated assays with routine screening protocols (Cobas HPV test combined with thinprep cytologic test(TCT) for the detection of cervical intraepithelial neoplasia in the general and hospital populations. The main questions it aims to answer are: - High-throughput HPV typing and integrated assays can screen for ≥ cervical intraepithelial neoplasia (CIN2 or CIN3) with high sensitivity and accuracy. - High-throughput HPV typing and integrated assays can be promoted as a screening tool for cervical cancer. Participants will be screened with routine screening protocols (Cobas HPV test combined with TCT test), and if the results are abnormal, colposcopy and cervical biopsy will be performed.


Description:

1. Stratified experimental design: Relying on the project's clinical multicenter to recruit patients for routine HPV screening in hospital outpatient clinics, for HPV high-risk type-positive subjects. The subjects with positive HPV types will continue to undergo TCT and colposcopic biopsy, and the remaining specimens after routine screening will be collected for high-throughput HPV typing and integrated assays. The sensitivity and accuracy of high-throughput HPV typing and integrated assays were compared with conventional screening methods. 2. Parallel experimental design: A multicenter cohort of 12,000 permanent residents was recruited for routine cervical cancer screening(HPV+TCT combined screening), and the remaining specimens were collected after the conventional screening to test the indexes of high-throughput HPV typing and integrated assays. The sensitivity and accuracy of high-throughput HPV typing and integrated assays were compared with conventional screening methods. 3. Prospective cohort study design: Based on a multicenter cohort of cervical cancer screening based on the project group, 3000 cervical cancer patients with HPV-positive routine screening and colposcopic biopsies were enrolled. The cohort was followed up regularly for 3 years with routine HPV+TCT and colposcopy, and cervical biopsy if necessary. And specimens remaining after routine screening will be collected for testing of high-throughput HPV typing and integrated assays. 4.subject selection: 1. .Stratified study design subjects were selected from patients who were first screened for cervical cancer in hospital outpatient clinics. 2. .Parallel trial design subjects were selected from resident female residents in a cohort of cervical cancer screening established by a clinical center. 3. .The prospective cohort study was designed to include HPV-positive patients in the cohort of cervical cancer screening established by the clinical center and whose cervical lesions were excluded by colposcopic biopsy. 5.This project is a multicenter prospective cohort study to investigate the immediate, 1st year, 2nd year and 3rd year cumulative risk of developing CIN2+ and CIN3+ in HPV 16 or 18-positive patients with positive and negative test results by integrating test results through a logistic Weibull model to assess whether colposcopy can be delayed and thus serve as a cervical cancer screening triage by comparing with risk values and clinical thresholds in the 2019 American Society for Colposcopy and Cervical Pathology(ASCCP)guidelines.


Recruitment information / eligibility

Status Recruiting
Enrollment 15000
Est. completion date November 30, 2024
Est. primary completion date November 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 25 Years to 70 Years
Eligibility Inclusion Criteria: 1. First screening. 2. History of sexual intercourse. Exclusion Criteria: 1. Previous CIN, cervical cancer or other cervical lesions; 2. History of cervical treatment; 3. Age <25, >70 years; 4. Pregnancy.

Study Design


Intervention

Diagnostic Test:
TCT test
These tests were performed on cervical exfoliated cells.
Vaginoscopy
To obtain the results of the patient's pathology report.
High throughput HPV typing and integration detection methods
This is screening for = cervical intraepithelial tumors (CIN2 or CIN3).
Cobas HPV test
To obtain HPV typing results.

Locations

Country Name City State
China Women's hospital school of medicine zhejiang university Hangzhou Zhejiang

Sponsors (3)

Lead Sponsor Collaborator
Women's Hospital School Of Medicine Zhejiang University Tongji Hospital, Wuhan Central Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the risk of cervical intraepithelial neoplasia(CIN) 2 or worse Patients who meet the requirements for referral colposcopy were further examined for CIN2+ by pathology. 3 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03196180 - Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia Early Phase 1
Active, not recruiting NCT04484415 - Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL) Phase 3
Not yet recruiting NCT06258564 - The Adjuvant Effect of HPV Vaccination on Recurrence of Cervical Precancer or Carcinoma in Women Undergoing Conization
Recruiting NCT04788849 - Extended VALidation of HUman Papillomavirus Assays and Collection DEvices for HPV Testing on Self-samples
Not yet recruiting NCT06273553 - A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3 Phase 1/Phase 2
Active, not recruiting NCT02149030 - Effectiveness of Cervical Screening in HPV Vaccinated Women Phase 4
Completed NCT01550783 - Home-Based or Clinic-Based Human Papillomavirus (HPV) Screening N/A
Enrolling by invitation NCT04755517 - Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women (HPV400) N/A
Completed NCT02811367 - The HPV Self-test as a Test of Cure in Madagascar N/A
Completed NCT00081263 - Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia Phase 2
Recruiting NCT05405270 - Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment
Completed NCT04312737 - Evaluation of in Vitro Devices on Self-collected Vaginal Swab and Urine Sample for Testing of Human Papilloma Virus
Completed NCT02067468 - Optimal Strategy for the Management of ASCUS Cytology in Health Care Services of Medellin, Colombia N/A
Completed NCT02354534 - Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3) Phase 1
Recruiting NCT03366493 - The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Lesion Detection Phase 3
Active, not recruiting NCT03064087 - Validation of Human Papillomavirus Assays and Collection Devices for Self-samples and Urine Samples
Recruiting NCT03274206 - A Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3) Phase 2